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Tweet:  
UK study shows that there is no significant association of past chlamydial exposure with 
spontaneous first trimester miscarriage - but observed past infection rates of >25% suggest 
that prevalence of Ct in young women remains underestimated @horne_research  
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Introduction: 
First trimester miscarriages are commonly associated with chromosomal abnormality of the 
embryo (~50% of cases)1. However, 15% of first trimester, and 66% of second trimester 
miscarriages, are attributed to reproductive tract infections2. It has been suggested that 
Chlamydia trachomatis (Ct) is a causative organism but its association with miscarriage is 
inconsistent2-4. This difference of opinion likely reflects the poor performance of major outer 
membrane protein (MOMP) peptide-based serology assays and the inability of nucleic acid 
amplification tests (that detect current infection) to detect prior exposure5. It is now possible 
to accurately measure lifetime exposure to Ct using an enzyme-linked immunosorbent assay 
(ELISA) that detects antibodies to the chlamydial plasmid-encoded protein Pgp35. This ELISA 
is more sensitive (73.8%) and specific (97.6%) than commercial ELISAs, including the Medac 
MOMP-petide ELISA, or previous serological antibody tests5. Pgp3 is unique to Ct, eliminating 
cross-reactivity with antibodies to C. pneumoniae infection (a common respiratory pathogen), 
a major weakness of previous serological tests. The aim of this study was to provide an 
estimation of the risk of prior Ct infection on spontaneous first trimester miscarriage. 
 
Methods: 
We performed a case-control study recruiting 251 women with an ultrasound confirming 
absence of a fetal heart in the first trimester of pregnancy (‘miscarriage group’) and 118 
women with normal pregnancies that had progressed into the third trimester from the same 
catchment population (‘controls’). Women with a past history of miscarriage were excluded 
from the controls. We anticipated a Ct seroprevalence of 15% in women with miscarriage and 
7% in the controls, based on literature review3 and pilot work, and our proposed sample size 
(200 cases, 100 controls) had >95% power, with a level of significance (alpha) of 0.05, to 
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estimate a doubling of the Ct-Population Attributable Risk for miscarriage. We collected 
serum samples and self-taken vulvo-vaginal swabs taken from 2-3 inches within the vagina 
for Ct nucleic acid amplification testing to detect current infection. The Scotland A Research 
Ethics Committee approved the study (12/SS/0098). Written informed consent was obtained 
from all participants. Participants were identified from the Pregnancy Support Unit and 
Delivery Suite at the Royal Infirmary of Edinburgh (a large UK NHS teaching hospital).  The first 
study participant was recruited on 22 January 2013 and the last participant recruited on 26 
September 2019. Analysis was by two-tailed Fisher’s exact test. 
 
Results: 
The groups were well balanced for all characteristics measured at baseline (see Table 1).  26% 
(CI:20.6-31.4) of the miscarriage group and 28% (CI:19.9-36.1) of the control group were PgP3 
antibody positive, suggesting prior infection with Ct (P=0.71). There was no evidence of active 
Ct infection in either group. More women in the miscarriage group (13.5%; CI:11.3-15.7) than 
the control group (1.7%; CI:0.5-2.9) self-reported past Ct infection (P=0.0001).  
 
Discussion: 
Contrary to the study by Baud et al3, which was conducted on a similar size dataset using a 
MOMP-peptide ELISA, our study, using the more sensitive Pgp3 ELISA, demonstrates that 
there is no significant association of past Ct exposure with spontaneous first trimester 
miscarriage. The lack of genetic analysis of the miscarriage and inability to match for past 
obstetric history are limitations of the study. It is unclear why more women in the miscarriage 
group self-reported Ct infection as recall bias is unlikely to explain such a difference. One 
possibility is that this may reflect that they were more likely to have had symptomatic Ct 
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infection and therefore seek testing.  However, the seroprevalence rates of over 25% 
observed in both cohorts suggests that the prevalence of Ct infection in young women, and 
potential clinical impact on other reproductive disorders, such as female infertility and ectopic 
pregnancy, remains underestimated.  
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Table 1. Summary data 
 
Characteristic Controls (n=118) Miscarriage group 
(n=251) 
 
Significance 
Median age in years  34 (CI: 32-35) 33 (CI: 32-35) P=0.72 
Mean BMI in kg/m2  26.0 (CI: 25.0-27.0) 25.6 (CI: 24.9-26.3) P=0.55 
Self-reported past Ct 
infection 
 
 2 (1.7%) 34 (13.5%) P=0.0001 **** 
Ct seropositivity  33 (28.0%) 65 (25.9%) P=0.71 
Prior miscarriage  - 106 (41.4%) - 
Prior live births  85 (72.0%) 127 (50.6%) P=0.0001**** 
History of smoking 
Never 75a (66.4%) 165b (66.8%) P=1.00 
Ex-smoker 27a (23.9%) 60b (24.3%) P=1.00 
Smoker 11a (9.7%) 22b (8.9%) P=0.84 
a113 and b247 responses 
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